Zymeworks Inc.

From conference presentations to peer-reviewed publications, we've recently shared new insights into our research and development efforts. If you missed them, here are a few recent highlights: - World Bispecific Summit Europe – view our presentation, Optimising Multispecific Antibody Design for Therapeutic Application: zymeworks.com/wp-content/upl… - Annals of Oncology – read Re-evaluating antibody—drug conjugate linker stability: assessment, interpretation, and clinical translation: sciencedirect.com/science/articl… - Clinical Cancer Research – read ZW191, an FRα-Targeted Topoisomerase 1 Inhibitor ADC with a Differentiated Antitumor Efficacy and Tolerability Profile: aacrjournals-org.ezzym.infotrieve.com/clincancerres/… To learn more about our research and antibody platforms, visit: zymeworks.com/antibody-scien… #DrugDiscovery #ADC #AntibodyEngineering #Oncology

Great science starts with great people. One of our favorite summer traditions is our annual employee-hosted patio party, where a different team takes the lead each year. This year's Summer Bytes event, co-hosted by our IT and HR teams, brought our Vancouver colleagues together for an afternoon of great food, fun, and connection. A big thank you to our organizers for such a fantastic event — we're already looking forward to seeing which team takes the reins next year! #LifeAtZymeworks #OneTeam #Biotech

If you're attending AACR D3 today, be sure to join our company presentation on our latest advances in antibody-drug conjugate (ADC) development. Company presentation: Grand Ballroom at 3:10 pm ET Dr. Raffaele Colombo will also be moderating "Drugging the Surfacesome – Session 1" from 4:45–6:15 pm ET in the Grand Ballroom. We hope to see you there! Learn more about our antibody platforms: zymeworks.com/antibody-scien… #AACRD3 #ADC #Oncology #DrugDiscovery

Our scientists continue to push the boundaries of next-generation immunotherapies, and we're proud to see their work featured at the Cell Engagers Microsummit. Join Gursev Anmole, Scientist & Group Lead at Zymeworks, on July 21 at 10 am PT as he presents "TriTCE Co-stim: A T-cell Engager Platform with Conditional cis CD28 Co-stimulation." Learn about more about our science: zymeworks.com/innovation/ #TCellEngagers #CancerResearch

Antibody-drug conjugates (ADCs) have emerged as an important class of anticancer therapeutics. Their highly modular design offers multiple opportunities to tune their properties and potentially improve clinical performance by modifying individual components, including the antibody, linker, and payload. In this article, our ADC Therapeutic Development team examines common assumptions regarding ADC linker stability, highlights limitations of preclinical models in predicting human payload exposure, outlines appropriate methods to assess ADC stability, and discusses the clinical implications of altering ADC linker stability. By re-evaluating the role of linker stability in #ADC design, this work aims to inform more rational strategies for the development of next-generation ADCs. Read the full article in Annals of Oncology (free access for 50 days): authors.elsevier.com/a/1nKG73I2OQqH…

Zymeworks will report its second quarter 2026 financial results after market close on August 6, 2026. Learn more: ir.zymeworks.com/news-releases/…

We're looking forward to the AACR D3 Conference in Boston next week. Raffaele Colombo will be presenting and participating in discussions on the latest advances in antibody-drug conjugate (ADC) development. Sessions: - Company Presentation: July 23 at 3:10 pm ET - Drugging the Surfacesome – Session 1: July 23 at 4:45–6:15 pm ET If you're attending, we'd love to connect! Learn more: aacr.org/meeting/aacr-d… #AACRD3 #AACR #ADC

This week, Zymeworks' Chief Scientific Officer, Paul Moore, presented "Optimising Multispecific Antibody Design for Therapeutic Application" at the World Bispecific Summit Europe. The presentation explored key considerations in the design of next-generation multispecific antibodies and highlights how our Azymetric™ platform enables the efficient generation of stable multispecific antibodies across a range of therapeutic formats. Case studies featured the breadth of the platform, spanning the approved HER2-targeting bispecific antibody, investigational bispecific antibody-drug conjugates and next-generation T-cell engagers. View the presentation here: zymeworks.com/wp-content/upl… #WorldBispecificSummit #MultispecificAntibodies #Biotech

Happy Independence Day! Today we recognize and celebrate our colleagues, collaborators and communities across the United States. We wish everyone celebrating a safe and enjoyable Fourth of July. #FourthOfJuly #Biotech

In case you missed it! At the 2026 T-Cell Engager Therapeutics Summit, Genevieve Desjardins presented "Enhancing the Activity of T-Cell Engagers in Solid Tumors with CD28 Co-Stimulation." The presentation highlights Zymeworks' innovative trispecific T-cell engager approach, which leverages conditional cis CD28 co-stimulation to enhance T-cell activation and anti-tumor activity while maintaining a favorable safety profile. Read the presentation: lnkd.in/gmgD9VcJ #tcellengagers #oncology

Happy Canada Day! Today we're celebrating our Canadian roots and the people who help drive our science forward every day. From our headquarters in Vancouver and across our global teams, we’re proud to contribute to Canada’s thriving life sciences ecosystem as we work to discover and develop new therapies for patients with difficult-to-treat diseases. Wishing everyone celebrating a safe and happy Canada Day. #CanadaDay #Biotech #LifeSciences

Today, we announced that we have entered into a definitive agreement to acquire Theravance Biopharma for approximately US$929 million. The proposed acquisition would add commercial and development-stage assets spanning COPD, inflammation and immunology, while further advancing Zymeworks' strategy to build a diversified biotechnology company with durable cash flows to support long-term innovation. More details here: ir.zymeworks.com/news-releases/…

Summer is officially here, and our annual company summer closure will run from June 26 to July 3, giving our dedicated team time to rest, recharge, and reconnect. We’re grateful for the opportunity to pause before an exciting second half of the year — one that includes important milestones across our pipeline, continued scientific collaboration, and presentations at key industry conferences. Thank you for your continued support as we prioritize employee well-being alongside innovation for patients. We’ll be back refreshed and ready for what’s ahead. #biotech #wellbeing

Today, we recognize Juneteenth — the oldest nationally celebrated commemoration marking the end of slavery in the United States and honoring the ongoing pursuit of freedom, justice, and equity. At Zymeworks, we recognize that advancing healthcare innovation also means helping address disparities in care and working toward a more equitable future in science and medicine. Learn more about Juneteenth here: nmaahc.si.edu/explore/moment… #Juneteenth #HealthEquity

We’re looking forward to attending the BIO International Convention next week! Join Dr. Sabeen Mekan, Chief Medical Officer, for Zymeworks’ company presentation on June 24 at 3:45 pm PT. The presentation will provide an overview of our company, differentiated pipeline, and approach to developing next-generation antibody-based therapeutics. Members of our Business Development team will be onsite throughout the conference and available to connect. If you'll be attending BIO, we’d love to meet with you and share more about Zymeworks' approach to developing next-generation therapeutics. Learn more about partnering with us here: zymeworks.com/partners/ #BIO2026

At the annual ESMO Gynaecological Cancers Conference this week, we will present an efficacy analysis of our folate receptor alpha (FRα) -targeting antibody-drug conjugate by (FRα) expression level. “We are highly encouraged by these data, which continue to demonstrate the differentiated profile of ZW191 and its potential to deliver meaningful clinical benefit across a broad population of patients with ovarian and endometrial cancers,” said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer of Zymeworks. “The response rate observed in FRα-positive ovarian cancer patients compares favorably with currently available therapies, while maintaining meaningful activity in patients with lower levels of FRα expression. Together these encouraging data on durability, progression-free survival, and manageable safety profile further strengthen our confidence in the program and reinforce the ability of our ADC platform to generate differentiated therapeutics.” View the poster: zymeworks.com/wp-content/upl… Read our press release: ir.zymeworks.com/news-releases/… #ADC #ESMOGYNE #ovariancancer #endometrialcancer

We're looking forward to attending the BIO International Convention later this month and connecting with colleagues, partners, and innovators from across the global life sciences community. Join Dr. Sabeen Mekan, Zymeworks' Chief Medical Officer, for the panel discussion "The Next Generation of ADCs: Building Kinder, Gentler Cancer Therapeutics" on June 25 at 10:15–11:15 am PT. We’ll also be delivering a company presentation highlighting Zymeworks' approach to developing novel antibody-based therapeutics on June 24 at 3:45 pm PT. Members of our Business Development and leadership teams will be onsite throughout the conference and available to connect. We look forward to discussing our science and partnership opportunities. See you at #BIO2026! #ADCs #TCellEngagers #BusinessDevelopment

We’re pleased to share that Dr. Sabeen Mekan will be participating in the CMO Summit panel discussion, “Existing Pipelines: Maintaining Clinical Progress” on June 16 at 8:30 am ET. The session will explore evolving regulatory considerations shaping the future of biotech innovation and drug development. Learn more: longwoodhealthcareleaders.com/events/mitceo2…

Today, on National Cancer Survivors Day, we recognize and celebrate the strength, resilience, and journeys of cancer survivors everywhere. At Zymeworks, patients remain at the center of everything we do. We are inspired by the courage of survivors and remain committed to advancing innovative therapies that aim to improve outcomes for people living with difficult to treat diseases. Learn about our programs: zymeworks.com/pipeline/ #CancerSurvivorsDay #Oncology

We’re excited to participate in the World Bispecific Summit in South Korea next week. Dr. Alexey Berezhnoy, Zymeworks' Senior Director of Immunology, will present “ZW1528, a Bispecific Antibody Targeting IL-4Ra & IL-33, Potently Inhibits Key Mediators of Airway Inflammation” and share insights into our continued work advancing next-generation multispecific therapeutics. View the conference program:worldbispecifics-tce-kr.com #COPD #bispecifics